Navigation Links
New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
Date:5/16/2008

ROCHESTER, Minn., May 16 /PRNewswire-USNewswire/ -- This release is being sent in a social media format, by Mayo Clinic in conjunction with the National Cancer Institute, part of the NIH.

News:

* A new study being presented at the American Society of Clinical Oncology meeting in Chicago (Abstract #4020), may change treatment practice in about 25 percent of patients with colon cancer and is the basis for proposed changes to the way colorectal cancers will be staged.

* This new study, using National Cancer Institute (NCI) SEER population-based statistic registries from 1992 to 2004, and phase III clinical trial data, shows that outcomes of patients with positive nodes (Stage III) in colorectal cancer interact, to a greater extent than previously thought, with how deeply the cancer penetrates the bowel wall.

* Survival outcomes depend on the thickness of the primary cancer within or beyond the bowel wall in addition to whether nodes are positive or negative. A patient with a node positive 'thin' lesion (i.e., confined to the bowel wall) has a stage III cancer with better survival outcomes than a patient with a Stage II node negative 'thick' cancer that penetrates beyond the bowel wall. The current standard of practice for colon cancer patients is that all or most Stage III patients receive chemotherapy after surgical removal of their cancer, but Stage II patients do not routinely receive chemotherapy. In a separate National Cancer Data Base (NCDB) analysis, patients with Stage III colon cancers confined to the bowel wall who did not receive chemotherapy still had better survival than Stage II patients.

* Guidelines for adjuvant therapy may need re-examination in future clinical trials as well as more research into the molecular basis for the interplay between a primary cancer's ability to penetrate the bowel wall and to spread to regional nodes.

* Also, the survival of patients whose cancers invade beyond the bowel wall to involve adjacent structures or organs is worse than that of patients whose cancers merely penetrate to the surface of the bowel wall (the reverse had been thought to be true).

* This abstract/poster will be presented by Dr. Leonard L. Gunderson, M.D., a radiation oncologist from Mayo Clinic, Scottsdale, Ariz., and Vice Chair of the Hindgut Task Force of the American Joint Commission on Cancer (AJCC) that proposes changes to current guidelines. J. Milburn Jessup, M.D., NCI, part of the National Institutes of Health, is the chair of the Task Force.

Quotes:

* J. Milburn Jessup, M.D.: "These proposed changes could lead to real clinical benefit for many colorectal cancer patients and also lessen the amount of treatment that patients with thin lesions may need."

* John E. Niederhuber, M.D., Director, NCI: "Simple advances in treatment that are derived by comparing national statistics to clinical data are greatly welcomed and are an excellent example of moving the field forward by some basic, low-cost methods."

* Leonard L. Gunderson, M.D.: "The current SEER analysis confirms that patients with node positive colon or rectal cancers that do not extend beyond the bowel wall have better survival than previously thought."

Multimedia:

* For still images related to colorectal cancer, go to: http://visualsonline.cancer.gov/details.cfm?imageid=1768; http://visualsonline.cancer.gov/details.cfm?imageid=2345

* For video of chemotherapy and other treatments, go to: http://www.cancer.gov/newscenter/pressreleases/b-roll-treatment.


'/>"/>
SOURCE Mayo Clinic Public Affairs; National Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New method proposed for determining which patients should get treatment for colorectal cancer
2. Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly $43 Million
3. Air Methods Corporation Confirms Fatal Accident in Wisconsin
4. Air Methods Reports 1Q2008 Results and 2Q2008 Update
5. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
6. New OPAL Therapy presents simple, cost-effective method of treating HIV infection
7. Air Methods to Report First Quarter Financial Results on Thursday, May 8, 2008
8. Determined a new method to establish the antioxidant capacity of extra virgin olive oil
9. Crime Scene Investigation methods could help in the battle against hospital infections
10. Air Methods Provides 1st Quarter Update
11. Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been announced Jack Uldrich, ... events throughout the month of May. , Uldrich is the author of 11 books ... also frequently appears on the Science Channel’s FutureScape and Discovery Channel’s Inside Out. , ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Pets bring ... a token of appreciation, pet owners celebrate National Pet Week, which falls on the ... 2016, remind pet owners to cherish the human-animal bond and recognize responsible pet ownership. ...
(Date:5/2/2016)... ... , ... “Engineering Bubbles,” an oil painting submitted by Canadian radiology resident Dr. ... at the Annual Meeting in Los Angeles. The first annual art forum was a ... Meeting attendees. , “Through art I hope to educate people about radiology and ...
(Date:5/2/2016)... ... 02, 2016 , ... Over $60 Billion is spent annually on products for ... leading product review site for Toys, Tots, Pets & More (TTPM) announced the 15 ... Showcase at the Metropolitan Pavilion in New York City. , Chosen from a field ...
(Date:5/2/2016)... ... May 02, 2016 , ... Zitter Health ... Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for their achievements in ... Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase of ... and an increase of 1.2% on an adjusted pro forma, ... quarter were $0.52 reported, a decrease of 47.5% from the ... over the prior year period , The Company increases ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ...
(Date:4/28/2016)... 28, 2016 TapImmune,Inc. (TPIV), ... peptide and gene-based immunotherapeutics and vaccines for the treatment of ... at the 3rd Annual Growth Capital Expo to ... 2016 at Caesars Palace in Las Vegas, Nevada.  The ... May 4 th by Dr. John N. Bonfiglio ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: